Peripheral mRNA-LNP Vaccination Generates Protective Brain-Resident Memory T Cells Against Intracranial Tumors

Technical Review | Journal of Clinical Investigation, 2026 | Mix, Stofer, Harken, Batista et al. | Featured Tool: PreciGenome NanoGenerator Flex®

Background

Brain tumors remain among the most lethal forms of cancer, with limited treatment options and poor prognosis. Despite advances in immunotherapy, durable responses in brain tumors remain elusive. A major barrier is the inability to establish persistent, functional immune surveillance within the brain parenchyma itself.

Tissue-resident memory (TRM) CD8+ T cells are non-circulating lymphocytes that persist at barrier tissues and provide rapid local immune defense. These cells have been well-characterized in skin, lung, and gut. However, whether TRM can be generated in the brain via peripheral vaccination and protect against intracranial malignancy was previously unknown. mRNA-LNP vaccines have emerged as a transformative immunization platform following the COVID-19 pandemic. This study by Mix et al. directly tested whether peripheral mRNA-LNP vaccination could generate tumor-specific brain TRM capable of protecting against intracranial tumors.

Figure 1. Tumor-specific brain TRM protect against intracranial tumor challenge. Mice were vaccinated with DC-rLM-OVA, treated with anti-Thy1.1 antibody to deplete circulating memory T cells, and challenged intracranially with B16-OVA melanoma. Tumor-specific TRM alone conferred significant survival benefit; bystander (P14) TRM did not protect, confirming antigen specificity. (Adapted from Mix et al., J Clin Invest, 2026)

Methodology

The researchers employed a multi-phase approach. OT-I TCR-transgenic CD8+ T cells combined with a dendritic cell prime / recombinant Listeria monocytogenes boost (DC-rLM) immunization strategy established the foundational proof-of-concept. To translate these findings, the authors developed a multi-epitope mRNA-LNP vaccine construct (UbMel-OVA) encoding melanoma-associated CD8+ T cell epitopes including TRP1, TRP2, GP100, and OVA, flanked by proteasomal cleavage sequences. The mRNA was packaged into LNPs using the PreciGenome NanoGenerator Flex microfluidic mixing system with a CHP-MIX-4 micromixer chip. The formulation used PreciGenome’s LipidFlex neutral lipid mixture (#PG-SYN_LF1ML) with cationic lipid SM-102, at an N/P ratio of 6:4, with a 3:1 aqueous-to-organic flow rate ratio at a total flow rate of 3 mL/min. LNP size was measured at 90–125 nm by dynamic light scattering.

Tumor-specific brain TRM provide durable protection

After vaccination, OT-I T cells seeded the brain and acquired canonical TRM markers including CD69, CD49a, and CXCR6. Critically, when circulating memory T cells were depleted via anti-Thy1.1 antibody treatment, mice harboring brain TRM were still protected against intracranial B16-OVA melanoma challenge. Brain TRM persisted for over 100 days and retained functional capacity upon intracranial rechallenge.

Figure 2. Brain TRM persist in tumor-surviving mice and confer durable protection upon rechallenge. OT-I TRM maintained expression of CD69 and CD49a in the brain parenchyma for over 100 days. Upon secondary intracranial challenge with concurrent TCIRCM depletion, TRM-harboring mice showed complete protection, confirming locally mediated immune surveillance. (Adapted from Mix et al., J Clin Invest, 2026)

Brain TRM restrain peripheral immunosuppression

Naive mice challenged with intracranial B16-OVA exhibited profound peripheral immunosuppression with decreased splenic weight, reduced thymic cellularity, and infiltration of myeloid cells into the brain. Mice harboring tumor-specific brain TRM were largely spared these pathological changes. Furthermore, OT-I brain TRM did not upregulate PD-1, suggesting that TRM-based protection operates through a sustained immune equilibrium rather than a conventional inflammatory response.

Figure 3. Brain TRM restrain tumor-associated peripheral immunosuppression and neuroinflammation. Mice with preexisting OT-I brain TRM showed preserved splenic weight, thymic cellularity, and normal peripheral immune cell numbers following intracranial challenge. UMAP analysis revealed minimal inflammatory infiltration in TRM-harboring mice. (Adapted from Mix et al., J Clin Invest, 2026)

Peripheral mRNA-LNP vaccination generates brain TRM

Mice prime-boosted with UbMel-OVA mRNA-LNP vaccine via intramuscular or intravenous administration generated OT-I T cells that seeded the brain and acquired canonical TRM signatures. Peripheral mRNA-LNP vaccination generated brain TRM that distributed widely throughout the brain, including near gray matter–white matter junction regions where metastasis-susceptible niches form.

Figure 4. Peripheral mRNA-LNP vaccination generates tumor-specific brain TRM. (A) UbMel-OVA mRNA-LNP vaccine construct design. (B) Prime-boost vaccination timeline. (C–F) OT-I expansion, brain seeding, and cytolytic responses. (G–H) Brain TRM expressed canonical markers regardless of vaccination route. (I) Immunohistochemistry showing TRM distribution at gray–white matter junctions. (J–L) Endogenous melanoma-specific CD8+ T cell responses. (Adapted from Mix et al., J Clin Invest, 2026)

mRNA-LNP vaccine-induced brain TRM durably protect against intracranial tumors

Mice prime-boosted with mRNA-LNP vaccines were treated with antibodies to deplete circulating T cells, then challenged intracranially with B16-OVA melanoma or GL261-QUAD-Luc glioblastoma cells. mRNA-LNP vaccination-induced brain TRM durably protected mice against both tumor types. In the GL261 glioblastoma model, vaccination substantially lowered tumor burden based on quantitative bioluminescence imaging. Tumor-specific brain TRM robustly proliferated and upregulated granzyme B expression, confirming active cytotoxic function.

Figure 5. mRNA-LNP vaccination-induced brain TRM durably protect against intracranial malignancy. (A) Experimental design with circulating T cell depletion before intracranial challenge. (B) Kaplan–Meier survival curves showing significant protection against B16-OVA. (C–E) Brain TRM maintained canonical phenotypic markers in surviving mice. (F) Survival in GL261-QUAD-Luc glioblastoma model. (G) Bioluminescence imaging confirmed reduced glioblastoma tumor burden. (Adapted from Mix et al., J Clin Invest, 2026)

Therapeutic mRNA-LNP vaccination outperforms checkpoint blockade

The researchers demonstrated that therapeutic mRNA-LNP vaccination, administered after tumor establishment using a subcutaneous B16-OVA model, outperformed anti-PD-L1 checkpoint blockade in controlling tumor growth and improving survival. Vaccine-induced CD8+ T cells were detected across multiple tissues with TRM-like phenotypes.

Figure 6. Therapeutic mRNA-LNP vaccination generates tumor-specific CD8+ T cells with TRM-like phenotypes. (A) Experimental design with post-tumor vaccination. (B–C) Tumor growth curves and survival showing mRNA-LNP vaccination outperformed anti-PD-L1 checkpoint blockade. (D–I) OVA-specific CD8+ T cells were detected across blood, spleen, liver, lung, and brain with TRM markers. (J–L) Peripheral tumor did not impair vaccine immunogenicity. (Adapted from Mix et al., J Clin Invest, 2026)

Key Findings at a Glance

Brain TRM alone are sufficient — tumor-specific brain TRM protect against intracranial tumors even when circulating memory T cells are depleted

Durable surveillance — brain TRM persist for over 100 days and remain fully protective upon rechallenge

Immunosuppression restraint — brain TRM prevent tumor-associated peripheral immunosuppression and neuroinflammation without PD-1 upregulation

mRNA-LNP vaccination works — peripheral mRNA-LNP vaccination generates brain TRM at gray–white matter junctions where metastases seed

Dual tumor protection — vaccine-induced brain TRM protect against both melanoma (B16-OVA) and glioblastoma (GL261-QUAD-Luc)

Outperforms checkpoint blockade — therapeutic mRNA-LNP vaccination outperformed anti-PD-L1 in the therapeutic setting

PreciGenome NanoGenerator Flex® — Featured Formulation Tool

The mRNA-LNP vaccines in this study were prepared using the PreciGenome NanoGenerator Flex microfluidic device with CHP-MIX-4 micromixer chip, cited directly by the authors. Using PreciGenome’s LipidFlex neutral lipid mixture (#PG-SYN_LF1ML) with SM-102 at an N/P ratio of 6:4, the system produced 90–125 nm LNPs optimized for mRNA delivery. Its precision microfluidic mixing enabled consistent antigen delivery that generated robust, long-lasting brain-resident immune responses — a critical requirement for cancer immunoprevention strategies.

Reference

Mix MR, Stofer CM, Harken MH, Batista VP, et al. “Peripheral vaccination-induced brain-resident memory CD8+ T cells durably protect mice against intracranial malignancy.” J Clin Invest. 2026;136(8):e197812.

DOI: 10.1172/JCI197812

Learn more about NanoGenerator Flex®: www.precigenome.com